Phase II study of 9-hydroxy-2N-methylellipticinium acetate

Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.

1982 • 35 citations

Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule

1982 • 28 citations

Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐Ellipticinium

1980 • 22 citations

Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)

1982 • 19 citations

Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals.

1980 • 12 citations